Abstract:Histone deacetylase (HDAC) has emerged as a new molecular target in the control of obesity and type 2 diabetes. HDAC is an enzyme with well-known functions in the regulation of chromatin structure and gene transcription in the nucleus, where HDAC interacts with corepressor proteins such as NcoR and SMRT to form active corepressor complexes. In the corepressor complex, HDAC catalyzes removal of acetyl groups from histone proteins to inhibit gene expression. Recent studies have consistently suggested that HDAC also exhibits activity in the cytosol and mitochondria to regulate acetylation of metabolic enzymes (1). More than 20% of mitochondria proteins are regulated by acetylation (2,3). Regulation of HDAC activity is a new approach to modify glucose and fatty acid metabolism in the treatment of type 2 diabetes. In HDAC, HDAC3 and sirtuin (SIRT)1 are well-known players in regulation of fatty acid and glucose metabolism. In mammals, HDACs are divided into three classes: class I HDACs (1–3,8,10), class II HDACs (4–7,9,11), and class III HDACs (SIRTs 1–7 and NAD-dependent histone deacetylases). Class I HDACs have strong catalytic activities, and they are targets of most HDAC inhibitors, such as trichostatin A (TSA), sodium butyrate, and suberoylanilide hydroxamic acid. HDAC3 regulates metabolism in genetic and pharmacological studies. NcoR is required by HDAC3 in the regulation of transcription factors including peroxisome proliferator–activated receptor (PPAR)γ. NcoR knockout in fat tissue led to enhanced PPARγ function in adipose tissue, increased insulin sensitivity, …

Histone Deacetylases and Their Inhibitors: Molecular Mechanisms and Therapeutic Implications in Diabetes Mellitus

Histone deacetylases and inhibitors in diabetes mellitus and its complications

Exploring histone deacetylases in type 2 diabetes mellitus: pathophysiological insights and therapeutic avenues

Roles of histone deacetylase inhibitors in treatment of diabetes mellitus

Histone Deacetylases in Modulating Cardiac Disease and Their Clinical Translational and Therapeutic Implications

Novel histone post-translational modifications in diabetes and complications of diabetes: The underlying mechanisms and implications

Histone Deacetylases in the Pathogenesis of Diabetic Cardiomyopathy

Improving Insulin Sensitivity with HDAC Inhibitor.

Histone deacetylases: Regulation of vascular homeostasis via endothelial cells and vascular smooth muscle cells and the role in vascular pathogenesis

Technologies of Targeting Histone Deacetylase in Drug Discovery: Current Progress and Emerging Prospects.

HDAC11, an Emerging Therapeutic Target for Metabolic Disorders

Targeting Histone Deacetylases: Perspectives for Epigenetic-Based Therapy in Cardio-Cerebrovascular Disease

Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.

Acetylated Histone Modifications: Intersection of Diabetes and Atherosclerosis

Mechanisms of HDAC (histone deaceitylase) on skeletal muscle energy metabolism

Advances in the Application of Histone Deacetylase Inhibitors in Eye Disease

Targeting histone deacetylases for heart diseases

Research advances in the use of histone deacetylase inhibitors for epigenetic targeting of cancer.

Role of histone deacetylases and their inhibitors in neurological diseases

Targeting histone deacetylases: Emerging applications beyond cancer

Targeting histone deacetylase in cardiac diseases